JNJ stock: buy or sell?

JNJ stock price: $134.94 3.04% At close on November 15th, 2019

Updated on:
November 15th, 2019


After sliding for 4 sessions, Nov/15 Johnson & Johnson soared a phenomenal 3.04%, closing at $134.94. November 15th session broke a read streak of 4 days.

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide.

Should I buy JNJ stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

Check the only buy setup that matches with Johnson & Johnson stock now:

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MAYes
100d MA crossing up 200d MANo

Is Johnson & Johnson stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At, we detected 14 ratings published for JNJ stock in the last month.

The general sentiment of these ratings is bullish for JNJ stock, with 11 positive ratings.
Is JNJ a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-8-27Morgan Stanleyn/aEqual Weight
2019-8-27Goldman Sachs Groupn/aBuy
2019-8-27Credit Suisse Groupn/aBuy
2019-7-18Credit Suisse Groupn/aBuy
2019-7-17Raymond Jamesn/aOutperform
2019-7-16Royal Bank of Canadan/aBuy
2019-7-16Bank of American/aHold
2019-7-12Credit Suisse Groupn/aOutperform
2019-5-6Wells Fargo & Con/aOutperform
2019-5-28Goldman Sachs Groupn/aBuy
2019-5-16Credit Suisse Groupn/aOutperform
2019-4-17Raymond JamesOutperformOutperform
2019-4-17Morgan StanleyEqual WeightEqual Weight
2019-4-17Credit Suisse GroupOutperformOutperform

JNJ stock analysis

Daily outlook

Johnson & Johnson broke up the simple moving average line of 200 days today and closed at $134.94, soared a 3.04%.

Johnson & Johnson broke up the SMA line of 200d today and closed at $134.94, soared a 3.04%.

JNJ stock chart (daily)

Weekly outlook

Johnson & Johnson crossed up the simple moving average line of 200d, closing at $134.94. Counting this, it's been 4 climbing weeks in a row, soaring a 5.51%.

Far behind is the all-time high Johnson & Johnson hit early December but price is just -7.52% below that top.

JNJ stock chart (weekly)

JNJ stock price history

JNJ IPO was on August 18th, 1980 at $0.01 per share1. Since then, JNJ stock surged a 1,349,300.00%, with a yearly average of 34,597.40%. If you had invested right after JNJ's IPO a $1,000 in JNJ stock in 1980, it would worth $13,493,000.00 today.

1: Adjusted price after possible price splits or reverse-splits.

JNJ stock historical price chart

JNJ stock reached all-time highs on December with a price of $145.91.

JNJ stock price target is $152.90

Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' JNJ stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we found 12 price targets for JNJ stock:
JNJ stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-8-27Morgan StanleyReiteratesn/a$145.00-
2019-8-27Goldman Sachs GroupSet Price Targetn/a$169.00-
2019-8-27Credit Suisse GroupSet Price Targetn/a$156.00-
2019-7-18Credit Suisse GroupSet Price Targetn/a$156.00-
2019-7-17Raymond JamesLowers Target$147.00$146.00-0.7%
2019-7-16Bank of AmericaReiteratesn/a$150.00-
2019-7-12Credit Suisse GroupInitiatesn/a$156.00-
2019-5-6Wells Fargo & CoReiterates$152.00$157.003.3%
2019-5-16Credit Suisse GroupRaises Target$152.00$156.002.6%
2019-4-17Raymond JamesRaises Target$145.00$147.001.4%
2019-4-17Morgan StanleyRaises Target$134.00$145.008.2%
2019-4-17Credit Suisse GroupRaises Target$151.00$152.000.7%
(in average)$146.80$152.904.0%
The price prediction for Johnson & Johnson stock is $152.90, moving in a range between $169.00 and $145.00. In average, analysts' outlook on JNJ price target is positive, improving the target by a 4.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

Since last April, when Johnson & Johnson presented its last earnings report, it . Unfortunately, reported EPS is not yet available in our database.
JNJ earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Johnson & Johnson annual sales jumped a very good 6.71% to $81,581.00 million dollars from $76,450.00 marked in 2017. Instead, its income margin (compared to sales) climbed to 18.75%, that is $15,297.00 million.

Johnson & Johnson fiscal year ends in December, and to compare its evolution since then, we estimate annual sales and income figures by adding results from the last 4 quarters. This is called TTM (or Twelve Trailing Months). So, Johnson & Johnson TTM sales up to March 2019 were $81,593.00 and earnings $14,679.00 M USD. When comparing this TTM figures with the last reported annuality, we can esteem Johnson & Johnson business evolution since December 2018: Annual turnover up to March, compared to lastest yearly report, stayed steady a tight 0.01%. Likewise, profit margin (net income/revenues) remained stable at 18.75%.

JNJ annual Sales and Income evolution
2013$71,260 M-$13,830 M19.4%-
2014$74,331 M4.31%$16,323 M22.0%18.03%
2015$70,074 M-5.73%$15,409 M22.0%-5.60%
2016$71,890 M2.59%$16,540 M23.0%7.34%
2017$76,450 M6.34%$1,300 M1.7%-92.14%
2018$81,581 M6.71%$15,297 M18.8%1,076.69%
TTM $81,593 M0.01%$14,679 M18.0%-4.04%

Quarterly financial results

Johnson & Johnson posted $20,021.00 million in revenues for 2019-Q1, a -1.83% less compared to previous quarter. Reported quarter income marked $3,749.00 million with a profit margin of 18.73%. Profit margin raised a 3.81% compared to previous quarter when profit margin was 14.92%. When comparing turnover to same quarter last year, Johnson & Johnson sales marked a neutral movement and remained constant a 0.06%.
JNJ quarterly Sales and Income evolution
2017-Q2$18,850 M-$3,830 M20.3%-
2017-Q3$19,650 M4.24%$3,760 M19.1%-1.83%
2017-Q4$20,195 M2.77%$-10,713 M-53.0%-384.92%
2018-Q1$20,009 M-0.92%$4,367 M21.8%-140.76%
2018-Q2$20,830 M4.10%$3,954 M19.0%-9.46%
2018-Q3$20,348 M-2.31%$3,934 M19.3%-0.51%
2018-Q4$20,394 M0.23%$3,042 M14.9%-22.67%
2019-Q1$20,021 M-1.83%$3,749 M18.7%23.24%

Johnson & Johnson ownership

When you are planning to invest in shares of a company, it's always worth to review its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Johnson & Johnson, 0.07% of all outstanding shares are owned by its staff.

In case of Johnson & Johnson stock, 69.23% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for JNJ stock account 0.00%, no big difference from last month.

For a better understanding, the next table shows ownership data compared to other related stocks:

Market cap$354.9 B$151.7 B$109.8 B$108.7 B$150.2 B
Total shares2,630.0 M1,770.0 M2,490.0 M960.1 M1,340.0 M
Float shares2,630.0 M1,760.0 M2,450.0 M842.1 M1,340.0 M
  - Institutional holdings (%)69.2%76.5%11.0%81.5%84.2%
  - Insider holdings (%)0.1%0.7%0.0%0.1%0.1%
Shares in short selling0.0%0.0%0.0%0.0%0.0%

JNJ summary

Friday, November 15th, 2019
Day range$130.78 - $134.97
Previous close$130.96
Session gain3.04%
Average true range$1.96
50d mov avg$130.79
100d mov avg$131.29
200d mov avg$133.55
Daily pattern
Weekly pattern

Johnson & Johnson performance

To better understand Johnson & Johnson performance you must compare its gains with other related stocks in same sector or industry. In the following table, we compare Johnson & Johnson performance to , GlaxoSmithKline, Eli Lilly and, Medtronic, Merck, Novartis, Pfizer, and Stryker:
LLYEli Lilly and3.00%-1.32%1.68%

Johnson & Johnson competitors

We selected a few stocks to conform a list of Johnson & Johnson competitors to check if you are interested in investing in JNJ:

Latest JNJ stock news